Parkinson's disease - challenges in new drug development

Collegium Antropologicum

Volumn 32, Issue 4, 2008, Pages 1275-1281

  Babić, Tomislav ^a   Mahović, Darija ^b  

^a I3 Research   (United Kingdom)

^b KBC Zagreb   (Croatia)

Author keywords

dopamine agonists; levodopa; Parkinson's disease; therapy

Indexed keywords

ANTIPARKINSON AGENT;

DRUG DESIGN; HUMAN; PARKINSON DISEASE; REVIEW;

ANTIPARKINSON AGENTS; DRUG DESIGN; HUMANS; PARKINSON DISEASE;

EID: 60249091322     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. RAJPUT ML, RAJPUT AH, Epidemiology of parkinsonism. In: FACTOR SA, WEINER WJ (Eds) Parkinson's disease: diagnosis and clinical management (Demos, New York, 2002.)
2. RIEDERER P, WUKETICH S, J Neural Transm, 38 (1976) 277.
3. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ, J Neurol Neurosurg Psychiatry, 55 (1992) 181.
4. GELB DJ, OLIVER E, GILMAN S, Arch Neurol, 56 (1999) 33.
5. HUGHES AJ, DANIEL SE, LEES AJ, Neurology, 57 (2001) 1497.
6. HUGHES AJ, BEN-SHLOMO Y, DANIEL SE, LEES AJ, Neurology, 42 (1992) 1142.
7. LITVAN I, BHATIA KP, BURN DJ, GOETZ CG, LANG AE, MCKEITH I, QUINN N, SETHI KD, SHULTS C, WEMMING GK, Mov Disord, 18 (2003) 467.
8. FAHN S, Ann NY Acad Sci, 991 (2003) 1.
9. ZAPPIA M, OLIVERI RL, MONTESANTI R, RIZZO M, BOSCO D, PLASTINI M, CRESCIBENE L, BASTONE L, AGUGLIA U, GAMBARDELLA A, QUATTRONE A, Neurology, 52 (1999) 763.
10. MUENTER MD, TYCE GM, Mayo Clin Proc, 46 (1971) 231.
11. OLANOW CW, WATTS RL, KOLLER WC, Neurology, 56 Suppl 5 (2001) S1-S88.
12. OLANOW CW, Annu Rev Med, 55 (2004) 41.
13. COLOSIMO C, DE MICHELE M, Eur J Neurol, 6 (1999)1.
14. CHAPUIS S, OUCHCHANE L, METZ O, GERBAUD L, DURIF F, Mov Disord, 20 (2005) 224.
15. KOSTIC V, PRZEDBORSKI S, FLASTER E, STERNIC N, Neurology,41 (1991) 202.
16. SCHRAG A, QUINN N, Brain, 123 (2000) 2297.
17. RILEY DE, LANG AE, Neurology, 43 (1993) 1459.
18. MOURADIAN MM, JUNCOS JL, FABBRINI G, SCHLEGEL J, BARTKO JJ, CHASE TN, Ann Neurol, 24 (1988) 372.
19. BLINDAUR K, Neurology, 60 Suppl 1 (2003) A81.
20. KOLLER WC, Neurology, 58 Suppl l1 (2002) S79-S86.
21. RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE, N Engl J Med, 342 (2000), 1484.
22. SCHAPIRA AH, OLANOW CW, Ann Neurol, 53 Suppl 3 (2003) S149-157.
23. NO AUTHORS LISTED, Clin Neuropharmacol, 23 (2000) 34.
24. WHONE AL, WATTS RL, STOESSL AJ, DAVIS M, RESKE S, NAHMIAS C, Ann Neurol, 54 (2003) 93.
25. STERN MB, Parkinsonism Rel Disord, 7 (2000) 27.
26. FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S, Neurology, 52 (1999) 1908.
27. RAZMY A, LANG AE, SHAPIRO CM, Arch Neurol, 61 (2004) 97.
28. SHAUNAK S, WILKINS A, PILLING JB, DICK DJ, J Neurol Neurosurg Psychiatry, 66 (1999) 79.
29. SERRATRICE J, DISDIER P, HABIB G, VIALLET F, WEILLER PJ, Cardiol Rev, 10 (2002) 334
30. LANIER WL,Mayo Clin Proc, 78 (2003) 684.
31. MOVEMENT DISORDER SOCIETY TASK FORCE ON RATING SCALES FOR PARKINSON'S DISEASE, Mov Disord, 18 (2003) 738.
32. CHAUDHURI KR, SCHAPIRA AHV, MARTINEZ-MARTIN P, ACNR, 4 (2004) 21.
33. DURIF F, DEBILLY B, GALITZKY M, MORAND D, VIALLET F, BORG M, THOBOIS S, BROUSSOLLE E, RASCOL O, Neurology, 62 (2004) 381.
34. CLARKE CE, ZOBKIW RM, GULLAKSEN E, Br J Clin Pract, 49 (1995) 288.
35. SHULMAN LM, TABACK RL, RABINSTEIN AA, WEINER WJ, Parkinsonism Relat Disord, 8 (2002) 193.
36. SLAUGHTER JR, SLAUGHTER KA, NICHOLS D, HOLMES SE, MARTENS MP, J Neuropsychiatry Clin Neurosci, 13 (2001) 187.
37. BENNETT DA, BECKETT LA, MURRAY AM, N Engl JMed., 334 (1996) 71.
38. LOUIS ED, MARDER K, COTE L, TANG M, MAYEUX R, Arch Neurol, 54 (1997) 260.
39. HOEHN MM, YAHR MD, Neurology, 17 (1967) 427.